These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38450197)

  • 41. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.
    van la Parra RFD; Tadros AB; Checka CM; Rauch GM; Lucci A; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
    Br J Surg; 2018 Apr; 105(5):535-543. PubMed ID: 29465744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer.
    Zhang J; Huang Y; Chen J; Wang X; Ma H
    World J Surg Oncol; 2021 Sep; 19(1):284. PubMed ID: 34537053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin.
    Frontiers Editorial Office
    Front Oncol; 2023; 13():1337635. PubMed ID: 38130993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retracted: Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.
    International BR
    Biomed Res Int; 2023; 2023():9784125. PubMed ID: 37388341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
    Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
    Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
    Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
    Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retraction: Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():709636. PubMed ID: 34178702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
    Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
    Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
    JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
    Wang C; Zhang J; Wang Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2015 Mar; 26(3):523-8. PubMed ID: 25480878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
    Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
    Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retraction: Effects of Aidi injection on life quality and incidence of adverse reactions in patients with non-small cell lung cancer compared with traditional chemotherapy: a systematic review and meta-analysis.
    Frontiers Editorial Office
    Front Oncol; 2024; 14():1383346. PubMed ID: 38440226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population.
    Zhang Y; Shen J; Wu S; Zhou Y; Shao Z; Liu G
    Surgery; 2020 Dec; 168(6):1115-1121. PubMed ID: 32917430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory Effect of miR497-5p-
    Cancer Manag Res; 2023; 15():1339-1340. PubMed ID: 38027234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study.
    Kim Y; Sim SH; Park B; Chae IH; Han JH; Jung SY; Lee S; Kwon Y; Park IH; Ko K; Lee CW; Lee KS; Kang HS; Lee ES
    Sci Rep; 2021 Jan; 11(1):634. PubMed ID: 33436702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The influence of various myelosuppression degrees during neoadjuvant chemotherapy on the curative effect and prognosis of triple-negative breast cancer].
    Niu YD; Zhang YW; Zhu RJ; Chu T; Wang L; Wang S; Li YY; Dong Y
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(29):2290-2294. PubMed ID: 35927061
    [No Abstract]   [Full Text] [Related]  

  • 58. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
    Liu L; Li XR; Hu YH; Zhang J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.
    Lin Y; Lin E; Li Y; Chen X; Chen M; Huang J; Guo W; Chen L; Wu L; Zhang X; Zhang W; Jin X; Zhang J; Fu F; Wang C
    Pathol Oncol Res; 2022; 28():1610559. PubMed ID: 36405394
    [No Abstract]   [Full Text] [Related]  

  • 60. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
    Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
    J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.